Soluble IFN-.beta.2/IL-6 binding protein its preparation, and pharmaceutical compositions containing it

• US 5,621,077 A
• Filed: 10/27/1994
• Issued: 04/15/1997
• Est. Priority Date: 06/01/1989
• Status: Expired due to Term

• Current Assignee: Yeda Research and Development Co. Ltd. (Weizmann Institute of Science)
• Original Assignee: Yeda Research and Development Co. Ltd. (Weizmann Institute of Science)
• Inventors: Chen, Louise, Rubinstein, Menachem, Wallach, David, Novick, Daniela, Engelmann, Hartmut, Revel, Michel
• Primary Examiner(s): ULM, JOHN D
• Application Number:
  US08/329,785
• Time in Patent Office: 901 Days
• Field of Search: 435/69.1, 530/350, 530/388.22, 514/2, 514/12, 514/21
• US Class Current: 530/350
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 38/215 IFN-beta
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: C07K 14/715 for cytokines; for lymphokines; for interferons
• CPC Class Codes: C07K 14/7155 for interleukins [IL]
• CPC Class Codes: Y10S 530/834 Urine; urinary system

Abstract

Human natural IFN-β2/IL-6 receptor and its soluble extracellular fragment are provided in substantially purified form and are shown to stimulate and to enhance beneficial effects of IFN-β2/IL-6, such as its antiproliferative activity. Polyclonal and monoclonal antibodies raised against the soluble fragment of the receptor are also provided.

Claims

1. Substantially purified protein having the same amino acid sequence as human interferon-β

2/interleukin-6 receptor (IFN-β

2/IL-6-R) soluble extracellular fragment, isolatable from human urine, having an apparent molecular weight of about 40-60K when analyzed by SDS-PAGE under non-reducing conditions, moving as a single peak on reversed-phase high performance liquid chromatography (HPLC), and containing the following N-terminal amino acid sequence;

Leu-Ala-Pro-Arg-Arg-Cys-Pro-Ala-Gln-Glu-Val-Ala-Arg-Gly-Val-Leu-Thr-Ser-Leu-Pro-Gly-Asp-Ser-Val-Thr-Leu-Thr-Cys-Pro-Gly-.

2. A protein in accordance with claim 1, comprising a recombinant protein.